BioPlus Acquisition マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

R. Ross Haghighat

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

更新なし

Recent updates

CEO（最高経営責任者

R. Ross Haghighat (59 yo)

no data

在職期間

Mr. R. Ross Haghighat serves as the Chief Executive Officer of Elecon, Inc. He serves as Chairman of the Board at FRX Innovations Inc. Mr. Haghighat is Managing Partner of Triton Systems, Inc., and Newbury...

BioPlus Acquisition マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Recent updates

BioPlus Acquisition Corp. Files Form 15

BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index

Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. (NasdaqGM:BIOS) from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.

BioPlus Acquisition Corp. (NasdaqGM:BIOS) entered into a definitive merger agreement to acquire Avertix, Inc. for approximately $170 million.

CEO（最高経営責任者

在職期間

BioPlus Acquisition マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Recent updates

BioPlus Acquisition Corp. Files Form 15

BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index

Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. (NasdaqGM:BIOS) from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.

BioPlus Acquisition Corp. (NasdaqGM:BIOS) entered into a definitive merger agreement to acquire Avertix, Inc. for approximately $170 million.

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04